SNCA and Parkinson disease: Moreover, in a multicenter retrospective study on PD patients with SNCA mutations that received bilateral STN-DBS, data for long-term outcomes were obtained, with sustained motor improvement in the patients with SNCA duplication and a significant decrease in the dose of levodopa in the patient with the SNCA missense c.158C.A (p.A53E) mutation.